MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Portfolio Pulse from
MiNK Therapeutics is set to present its iNKT cell therapy, agenT-797, for refractory gastric cancer at the ASCO GI Annual Meeting. The presentation will focus on the ongoing Phase 2 study of this therapy.
December 18, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MiNK Therapeutics will present its iNKT cell therapy, agenT-797, at the ASCO GI Annual Meeting, highlighting its Phase 2 study in refractory gastric cancer.
The presentation at a major conference like ASCO GI can increase visibility and credibility for MiNK Therapeutics' iNKT cell therapy. Positive results from the Phase 2 study could lead to increased investor interest and potential partnerships.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90